Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination

Prospective, Non-interventional Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination, in a Greek Population With Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02655029

Acronym

CONTROL-3

Enrollment

2285

Registered

2016-01-13

Start date

2015-11-25

Completion date

2016-12-21

Last updated

2017-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence to Medication Regime, Hypertensive Disease

Brief summary

The main objective of this study is to record, in routine clinical practice, patients' adherence to treatment with Perindopril/Indapamide/Amlodipine fixed dose combination, during 4 months treatment.

Detailed description

This is a non-interventional study aiming to record adherence to treatment with Perindopril/Indapamide/Amlodipine fixed dose combination. In parallel blood pressure levels will be recorded, as well as safety and tolerability of this fixed dose combination.

Interventions

DRUGPerindopril/Indapamide/Amlodipine fixed dose combination

Dose selection is based on investigators management.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female, ambulatory patients \>18 years old. * Clinically diagnosed essential arterial hypertension. * Under treatment with Perindoril/Indapamide/Amlodipine fixed dose combination. * The patient has given his/her written consent after being informed, before his inclusion in the study.

Exclusion criteria

* Secondary arterial hypertension. * Serious end stage diseases, severe neuropsychiatric diseases, cerebrovascular event with serious residual lesions, scheduled procedure or surgical operation or hospital admission. * Pregnancy, lactation or intention to become pregnant.

Design outcomes

Primary

Measure	Time frame	Description
Adherence to treatment	Change of total score of compliance scale between baseline and 1st month and between 1st and 4th month of treatment	Total score of Hill-Bone High Blood Pressure Compliance Scale will be recorded at each study visit

Secondary

Measure	Time frame
Systolic Blood Pressure	All visits (baseline, 1st and 4th month of treatment)
Diastolic Blood Pressure	All visits (baseline, 1st and 4th month of treatment)
Adverse events recording leading to treatment discontinuation	1st and 4th month of treatment

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026